CollPlant Biotechnologies (CLGN) posted a second quarter net loss of $4.21 million or $0.37 per share compared to profit of $5.76 million or $0.49 per share, a year ago. Non-GAAP net loss was $3.8 million, or $0.33 per share, compared to net income of $6.0 million, or $0.53 basic per share, prior year.
Revenue was $249 thousand compared to $10.18 million. The company said the decrease in revenues is mainly related to the achievement of a milestone with respect to the AbbVie agreement, which triggered a $10 million payment in 2023.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.